KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
Overview of attention for article published in Future Oncology, February 2019
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (91st percentile)
-
High Attention Score compared to outputs of the same age and source (90th percentile)
Mentioned by
- news
- 1 news outlet
- policy
- 1 policy source
- 4 X users
- patent
- 1 patent
- video
- 1 YouTube creator
- podcasts
- 1 podcast
Readers on
- mendeley
- 164 Mendeley